Inhibitory effect of compounds from Zingiberaceae species on human platelet aggregation.

Department of Pharmacy, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Malaysia.
Phytomedicine: international journal of phytotherapy and phytopharmacology (Impact Factor: 2.97). 05/2008; 15(4):306-9. DOI: 10.1016/j.phymed.2007.08.002
Source: PubMed

ABSTRACT Twelve compounds isolated from Alpinia mutica Roxb., Kaempferia rotunda Linn., Curcuma xanthorhiza Roxb., Curcuma aromatica Valeton and Zingiber zerumbet Smith (Family: Zingiberaceae) and three synthesized derivatives of xanthorrhizol were evaluated for their ability to inhibit arachidonic acid- (AA), collagen- and ADP-induced platelet aggregation in human whole blood. Antiplatelet activity of the compounds was measured in vitro by the Chrono Log whole blood aggregometer using an electrical impedance method. Among the compounds tested, curcumin from C. aromatica, cardamonin, pinocembrine and 5,6-dehydrokawain from A. mutica and 3-deacetylcrotepoxide from K. rotunda showed strong inhibition on platelet aggregation induced by AA with IC(50) values of less than 84 microM. Curcumin was the most effective antiplatelet compound as it inhibited AA-, collagen- and ADP-induced platelet aggregation with IC(50) values of 37.5, 60.9 and 45.7 microM, respectively.

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: Several curcuminoids have been identified from rhizome of the common spice Curcuma longa (Zingaberaceae) and related plant species. Curcuminoids are known to display several pharmacological properties summed up in numerous papers and reviews. In addition to curcuminoids, more than 250 mono-, sesqui- di-, and triterpenoids have been identified from curcuma species. These lipophilic compounds have better absorption than curcuminoids and also exhibit a wide spectrum of pharmacological properties. Little attention has been paid to these lipophilic compounds, which may be as physiologically active, if not more, as curcuminoids. This review focuses on Curcuma terpenoids and their physiological properties.
    Journal of Biologically Active Products from Nature. 02/2013; 3(1):1-55.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this investigation is to evaluate the anticancer properties of zerumbone (ZER) on the Jurkat human T- cell line using MTT assay, microscopic evaluations, flow cytometry, and caspase activity. The results showed that ZER is selectively cytotoxic to Jurkat cells in a dose and time-dependent manner with IC50 of 11.87 ± 0.17, 8.59 ± 0.48 and 5.39 ± 0.43 μg/mL at 24, 48 and 72 h of treatment respectively. Whereas, the trypan blue exclusion assay showed that ZER did not produce adverse effect on normal human peripheral blood mononuclear cells (PBMC). Comparatively, doxorubicin (positive control) imposed an inhibitory effect on Jurkat cells with an IC50 of 2.11 ± 0.2, 1.77 ± 0.15, 1.51 ± 0.07 μg/mL after 24, 48 and 72 h treatment, respectively. ZER significantly (P<0.05) arrested Jurkat cells at G2/M phase. On the other hand, we revealed that, the antiproliferative effect of ZER on Jurkat cells was through the apoptotic intrinsic pathway via activation of caspases ˗3 and ˗9. The results revealed that ZER can be further developed as a chemotherapeutic compound for the treatment of cancers especially leukemia.
    Natural product communications 09/2014; 9(9):1237-1242. · 0.92 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Authors may reproduce/republish portions of their published contribution without seeking permission from NPC, provided that any such republication is accompanied by an acknowledgment (original citation)-Reproduced by permission of Natural Product Communications. Any unauthorized reproduction, transmission or storage may result in either civil or criminal liability. The publication of each of the articles contained herein is protected by copyright. Except as allowed under national "fair use" laws, copying is not permitted by any means or for any purpose, such as for distribution to any third party (whether by sale, loan, gift, or otherwise); as agent (express or implied) of any third party; for purposes of advertising or promotion; or to create collective or derivative works. Such permission requests, or other inquiries, should be addressed to the Natural Product Inc. (NPI). A photocopy license is available from the NPI for institutional subscribers that need to make multiple copies of single articles for internal study or research purposes.
    Natural product communications 09/2014; 2395(2):1555-9475795. · 0.92 Impact Factor